EP2227496A1 - Kationische betainvorläufer für zwitterionische betaine mit kontrollierten biologischen eigenschaften - Google Patents
Kationische betainvorläufer für zwitterionische betaine mit kontrollierten biologischen eigenschaftenInfo
- Publication number
- EP2227496A1 EP2227496A1 EP08851463A EP08851463A EP2227496A1 EP 2227496 A1 EP2227496 A1 EP 2227496A1 EP 08851463 A EP08851463 A EP 08851463A EP 08851463 A EP08851463 A EP 08851463A EP 2227496 A1 EP2227496 A1 EP 2227496A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polymer
- group
- cationic
- compound
- hydrolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002091 cationic group Chemical group 0.000 title claims description 40
- 239000002243 precursor Substances 0.000 title description 4
- 230000004071 biological effect Effects 0.000 title description 3
- 229920000642 polymer Polymers 0.000 claims abstract description 212
- 229920006317 cationic polymer Polymers 0.000 claims abstract description 104
- 239000000178 monomer Substances 0.000 claims abstract description 59
- 239000003814 drug Substances 0.000 claims abstract description 49
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 19
- 230000007062 hydrolysis Effects 0.000 claims description 97
- 238000006460 hydrolysis reaction Methods 0.000 claims description 97
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 150000002500 ions Chemical class 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 230000000845 anti-microbial effect Effects 0.000 claims description 41
- 229920001577 copolymer Polymers 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- -1 tetrafluoroborate Chemical compound 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 22
- 230000002209 hydrophobic effect Effects 0.000 claims description 20
- 230000000844 anti-bacterial effect Effects 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 239000004599 antimicrobial Substances 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 10
- 229920001519 homopolymer Polymers 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000000129 anionic group Chemical group 0.000 claims description 9
- 229940121375 antifungal agent Drugs 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 229920005604 random copolymer Polymers 0.000 claims description 9
- 229960001860 salicylate Drugs 0.000 claims description 9
- 229920001400 block copolymer Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 239000003429 antifungal agent Substances 0.000 claims description 7
- 238000001476 gene delivery Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 229910052698 phosphorus Inorganic materials 0.000 claims description 7
- 230000000379 polymerizing effect Effects 0.000 claims description 7
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims description 5
- 150000007942 carboxylates Chemical class 0.000 claims description 5
- 239000007943 implant Substances 0.000 claims description 5
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 4
- ZXMGHDIOOHOAAE-UHFFFAOYSA-N 1,1,1-trifluoro-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NS(=O)(=O)C(F)(F)F ZXMGHDIOOHOAAE-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-O hydron piperazine Chemical compound [H+].C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-O 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-O hydron;pyrimidine Chemical compound C1=CN=C[NH+]=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-O 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 claims description 4
- 125000000962 organic group Chemical group 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 229910006389 Li—N Inorganic materials 0.000 claims description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 claims description 3
- 108700005077 Viral Genes Proteins 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 210000001367 artery Anatomy 0.000 claims description 3
- 239000002473 artificial blood Substances 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 210000003709 heart valve Anatomy 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000003106 tissue adhesive Substances 0.000 claims description 3
- 239000002407 tissue scaffold Substances 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 230000002861 ventricular Effects 0.000 claims description 3
- 150000001767 cationic compounds Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000001302 tertiary amino group Chemical group 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 34
- 238000001179 sorption measurement Methods 0.000 description 33
- 239000000463 material Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 27
- 150000002148 esters Chemical class 0.000 description 26
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 20
- 230000001580 bacterial effect Effects 0.000 description 19
- 102000008946 Fibrinogen Human genes 0.000 description 18
- 108010049003 Fibrinogen Proteins 0.000 description 18
- 229940012952 fibrinogen Drugs 0.000 description 18
- 239000002105 nanoparticle Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 17
- 229960004889 salicylic acid Drugs 0.000 description 17
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 125000005647 linker group Chemical group 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 238000000576 coating method Methods 0.000 description 15
- 239000000017 hydrogel Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 229920002873 Polyethylenimine Polymers 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 9
- 125000004185 ester group Chemical group 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 125000006850 spacer group Chemical group 0.000 description 8
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 7
- 229910052737 gold Inorganic materials 0.000 description 7
- 239000010931 gold Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000010065 bacterial adhesion Effects 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241001646716 Escherichia coli K-12 Species 0.000 description 5
- 239000012620 biological material Substances 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 5
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 4
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical group CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 230000032770 biofilm formation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- ADTJPOBHAXXXFS-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]prop-2-enamide Chemical compound CN(C)CCCNC(=O)C=C ADTJPOBHAXXXFS-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940117986 sulfobetaine Drugs 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- JVQTWZGZUCJHRV-UHFFFAOYSA-N 11-sulfanylundecyl 2-bromo-2-methylpropanoate Chemical compound CC(C)(Br)C(=O)OCCCCCCCCCCCS JVQTWZGZUCJHRV-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- YOCIJWAHRAJQFT-UHFFFAOYSA-N 2-bromo-2-methylpropanoyl bromide Chemical compound CC(C)(Br)C(Br)=O YOCIJWAHRAJQFT-UHFFFAOYSA-N 0.000 description 3
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 3
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 150000001450 anions Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VHBSECWYEFJRNV-UHFFFAOYSA-N 2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.OC(=O)C1=CC=CC=C1O VHBSECWYEFJRNV-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 239000008001 CAPS buffer Substances 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000012480 LAL reagent Substances 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 2
- DXBULVYHTICWKT-UHFFFAOYSA-N ethyl 6-bromohexanoate Chemical compound CCOC(=O)CCCCCBr DXBULVYHTICWKT-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 150000003902 salicylic acid esters Chemical group 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ULGGZAVAARQJCS-UHFFFAOYSA-N 11-sulfanylundecan-1-ol Chemical compound OCCCCCCCCCCCS ULGGZAVAARQJCS-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 239000004593 Epoxy Chemical group 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical group F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229920002118 antimicrobial polymer Polymers 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 239000002977 biomimetic material Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000013580 millipore water Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003008 phosphonic acid esters Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000636 poly(norbornene) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001485 positron annihilation lifetime spectroscopy Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003453 sulfinic acid esters Chemical class 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/10—Esters
- C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
- C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/10—Esters
- C08F120/38—Esters containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
- C08F20/10—Esters
- C08F20/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
- C08F20/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
- C08F20/10—Esters
- C08F20/38—Esters containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
- C08F20/52—Amides or imides
- C08F20/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
- C08F220/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
- A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
- A61K2800/5426—Polymers characterized by specific structures/properties characterized by the charge cationic
Definitions
- Cationic polymers have many unique biological, chemical, and mechanical properties. It is well known that cationic polymers can condense DNA or proteins or proteins for gene or drug delivery. Polycations can be used as an antimicrobial agent to disrupt the membranes of bacteria. However, cationic polymers present cell toxicity and tend to bind proteins that restricts their biomedical applications. For antimicrobial materials, killed microbes can accumulate on the surfaces and decrease their antimicrobial activities.
- the present invention provides cationic polymers that are hydrolyzable to zwitterionic polymers, cationic monomers that are polymerizable to provide the cationic polymers, surfaces coated with the cationic polymers, methods for applying the cationic polymers to surfaces, therapeutic agent delivery systems that include the cationic polymers, methods for delivering therapeutic agents using the cationic polymers, and methods for making the cationic polymers and the cationic monomers.
- the invention a cationic polymer that is hydrolyzable to a zwitterionic polymer.
- the cationic polymer comprises: (a) polymer backbone;
- a hydrolyzable group covalently coupled to each cationic center through a second linker wherein the hydrolyzable group is hydrolyzable to an anionic center to provide a zwitterionic polymer having the anionic center covalently coupled to the cationic center through the second linker.
- the cationic polymer has the formula:
- the counter ion is a hydrophobic organic counter ion.
- Representative hydrophobic organic counter ions include C1-C20 carboxylates and C 1 -C20 alkylsulfonates .
- the counter ion is a therapeutic agent.
- Representative therapeutic agents include antimicrobial, antibacterial, and antifungal agents.
- the therapeutic agent is a salicylate.
- the counter ion is selected from nucleic acids (e.g., DNAs, RNAs, and siRNAs), amino acids, proteins, and peptides.
- nucleic acids e.g., DNAs, RNAs, and siRNAs
- amino acids e.g., amino acids, proteins, and peptides.
- the hydrolyzable group releases a hydrophobic organic group on hydrolysis.
- Representative hydrophobic organic groups include C4-C20 carboxylates (e.g., n-C4-C20 alkyl-CO 2 " ).
- the hydrolyzable group releases a therapeutic agent on hydrolysis.
- Representative therapeutic agents include antimicrobial, antibacterial, and antifungal agents.
- the therapeutic agent is a salicylate.
- the cationic center is selected from ammonium, imidazolium, triazaolium, pyridinium, morpholinium, oxazolidinium, pyrazinium, pyridazinium, pyrimidinium, piperazinium, and pyrrolidinium cationic centers.
- R a and R b are independently selected from the group consisting of Cl-ClO straight chain and branched alkyl groups.
- L 2 is -(CH 2 ) n -, where n is an integer from 1 to 20.
- A is selected from the group consisting of C, SO, and PO.
- R c is C4-C20 alkyl.
- X " is selected from halides, carboxylates, alkylsulfonates, sulfate; nitrate, perchlorate, tetrafluoroborate, hexafluorophosphate, trifluoromethylsulfonate, bis(trifluoromethylsulfonyl)amide, lactate, and salicylate.
- the invention provides monomers for making the cationic polymers of the invention.
- the monomer is a cationic compound, comprising:
- the compound has the formula
- CH 2 C(R d ) is the polymerizable group
- R d is selected from the group consisting of hydrogen, fluorine, trifluoromethyl, and C1-C6 alkyl
- N + is the cationic center
- R a and R b are independently selected from hydrogen, alkyl, and aryl
- L 1 is a linker that covalently couples the cationic center to the polymerizable group
- L 2 is a linker that covalently couples the cationic center to the hydrolyzable group
- X " is the counter ion associated with the cationic center.
- the invention provides polymers obtainable from polymerizing one or more of the monomers described above.
- the polymers obtainable from polymerizing one or more of the monomers described above are homopolymers.
- the polymers are copolymers.
- Representative copolymers include random and block copolymers.
- the copolymers are obtainable by copolymerizing one or more of the monomers described above with one or more second co-monomers.
- Representative co-monomers include polymerizable zwitterionic monomers, hydrophobic monomers, and anionic monomers.
- the polymers obtainable from the cationic monomers of the invention has a plurality of repeating units, with the repeating units having the formula:
- -[CH 2 -C(R d )L- defines a polymer backbone having n repeating units;
- Ra is selected from the group consisting of hydrogen, fluorine, trifluoromethyl, and C1-C6 alkyl; n is 10 to 10,000;
- N + is a cationic center;
- R a and R b are independently selected from hydrogen, alkyl, and aryl;
- L 1 is a linker that covalently couples the cationic center to the polymer backbone;
- L 2 is a linker that covalently couples the cationic center to the hydrolyzable group;
- X " is the counter ion associated with the cationic
- the polymer is a homopolymer. In one embodiment, the polymer is a copolymer. In one embodiment, the copolymer is a random copolymer. In another embodiment, the copolymer is a block copolymer. In other embodiments, the copolymer includes a repeating unit selected from hydrophobic repeating units, anionic repeating units, and zwitterionic repeating units.
- the invention provides surfaces that are treated with, coated with, modified by, or otherwise incorporates one or more polymers of the invention.
- the invention provides a surface of a substrate that has been treated with, coated with, modified by, or otherwise incorporates one or more polymers of the invention.
- Representative substrates include particles, drug carriers, non-viral gene delivery systems, biosensors, membranes, implantable sensors, subcutaneous sensors, implants, and contact lenses.
- Other representative substrates include implantable medical devices such as ear drainage tubes, feeding tubes, glaucoma drainage tubes, hydrocephalous shunts, keratoprostheses, nerve guidance tubes, urinary catheters, tissue adhesives, x-ray guides, artificial joints, artificial heart valves, artificial blood vessels, pacemakers, left ventricular assist devices (LVADs), artery grafts, tissue scaffolds, and stents.
- implantable medical devices such as ear drainage tubes, feeding tubes, glaucoma drainage tubes, hydrocephalous shunts, keratoprostheses, nerve guidance tubes, urinary catheters, tissue adhesives, x-ray guides, artificial joints, artificial heart valves, artificial blood vessels, pacemakers, left ventricular assist devices (LVADs), artery grafts, tissue scaffolds, and stents.
- Methods for applying, coating, modifying, or otherwise incorporating one or more polymers of the invention onto a surface of a substrate are also provided.
- the polymers can be directly applied to
- the therapeutic agent delivery system includes a polymer of the invention and a therapeutic agent that is reversibly associative with the polymer.
- Representative therapeutic agents include small molecules, nucleic acids, amino acids, peptides, and proteins.
- the therapeutic agent is a nucleic acid such as a DNA, RNA, or siRNA.
- the polymer is a copolymer.
- Representative copolymers have first repeating units and second repeating units. Suitable first repeating units include tertiary (3°) amine groups and suitable second repeating units include primary (1°), secondary (2°), or quaternary (4°) amine groups.
- copolymers can be designated 3°/l°, 3°/2°, and 3°/4°.
- the second repeating units include quaternary amine groups (e.g., 3°/4° copolymer).
- the copolymers are random copolymers.
- the copolymers are block copolymers.
- the invention provides methods for administering a therapeutic agent using a cationic polymer of the invention. In the method, a therapeutic agent is administered to a subject in need thereof by administering a therapeutic agent delivery system that includes a polymer of the invention and a therapeutic agent that is reversibly associative with the polymer.
- FIGURE 1 illustrates the structures of three representative cationic monomers useful for making cationic polymers of the invention: three acrylamide monomers with different carboxybetaine ester groups; CBAA- 1-ester, CBAA-3-ester, and CBAA-5-ester.
- FIGURE 2 illustrates the hydrolysis of a representative cationic polymer of the invention: hydrolysis of a cationic polycarboxybetaine ester to zwitterionic polycarboxybetaine.
- FIGURE 3 compares the 1 H NMR spectra of the hydrolysis of a representative cationic polymer of the invention, polyCBAA-3-ester, after one -hour treatment in a solution with the sodium hydroxide concentration of (a) 10 mM (3% hydrolysis), (b) 100 mM (82% hydrolysis), and (c) 1 M (100% hydrolysis).
- FIGURE 4 compares the hydrolysis rates of representative cationic polymers of the invention at 10 mM and 100 mM aqueous sodium hydroxide.
- FIGURES 5A-5C are SPR sensorgrams for fibrinogen adsorption on the surfaces grafted with representative polymers of the invention: polycarboxybetaine esters before and after hydrolysis; (a) polyCBAA- 1-ester, (b) polyCBAA-3-ester, and (c) polyCBAA- 5-ester. The surfaces with polymer brushes were hydrolyzed with a 100 mm NaOH solution for l-2h.
- FIGURE 6 is a graph comparing antimicrobial activities of three representative cationic polymers of the invention, polyCBAA-esters, before and after hydrolysis. E. coli (10 8 cells/mL) was incubated with each polymer solution (repeat unit molar concentration: 2 mM) for 30 min. PBS buffer (pH 7.4 and 150 mM) is used as a negative control.
- FIGURE 7 is a schematic illustration of a representative surface of the invention coated with a cationic polymer.
- the surface switches from an antibacterial surface to a non-fouling surface upon hydrolysis: (a) antimicrobial cationic pCBMA-1 C2 effectively kills bacteria, (b) pCBMA-1 C2 is converted to non-fouling zwitterionic pCBMA-1 upon hydrolysis, (c) killed bacteria remaining on the surface is released from non-fouling zwitterionic pCBMA-1 demonstrating that (d) zwitterionic pCBMA-1 itself is highly resistant to bacterial adhesion.
- FIGURE 8 illustrates the chemical structures of a representative cationic polymer of the invention, switchable pCBMA-1 C2; antimicrobial cationic pC8NMA; and non-fouling zwitterionic pCBMA-2.
- FIGURES 1OA - 1OF are fluorescence microscopy images of attached E. coli
- K12 cells red color
- Hydrolysis was for 8 days with 1OmM CAPS (pH 10.0).
- FIGURE 12A compares SPR sensorgrams showing the adsorption of 1 mg mL "1 fibrinogen in PBS buffer on the surfaces grafted with pCBMA-1 C2 via ATRP (a) before hydrolysis, and (b), (c) and (d) after 24 hr hydrolysis with water, 10 mM CEHS at pH 9.0, and 10 mM CAPS at pH 10.0, respectively;
- FIGURE 12B compares SPR sensorgrams showing the adsorption of 1 mgmL "1 fibrinogen in PBS buffer on the surfaces grafted with pC8NMA (a) before and (b) after 24 hr incubation with 1OmM CAPS at pH 10.0, and on the surfaces grafted with pCBMA-2 (c) before hydrolysis and (d) after 24 h of hydrolysis with 1OmM CAPS at pH 10.0.
- FIGURE 13 illustrates the structure of a representative cationic monomers useful for making cationic polymers of the invention: CBMA-I C2 SA, the ethyl ester of CBMA-I having a salicylate counter ion.
- FIGURE 14 compares the release rate (mg/h) of salicylic acid over time (12 h,
- FIGURE 15 compares the release rate (mg/h) of salicylic acid over time (12 h, 39 h, and 63 h) at 37 0 C under four conditions from hydrogels prepared by polymerizing CBMA-I C2 SA: (a) water, neutral pH; (b) phosphate buffered saline (PBS); (c) water, pH 10; and (d) 0.15 M aqueous sodium chloride, pH 10.
- PBS phosphate buffered saline
- FIGURE 16 is a photograph of an agarose electrophoresis gel illustrating electrophoresis retardation of DNA complexes with representative cationic polymers of the invention: lane 1, DNA only; lane 2, polyCBAA-1-ester/DNA; lane 3, hydrolyzed polyCBAA-1-ester/DNA; lane 4, polyCBAA-3-ester/DNA; lane 5, hydrolyzed polyCBAA-3-ester/DNA; lane 6, polyCBAA-5-ester/DNA; and lane 7, hydrolyzed polyCBAA-5-ester/DNA.
- FIGURE 17 illustrates the structures of secondary (2°) and tertiary (3°) analogs of quaternary (4°) carboxybetaine methacrylate ethyl ester monomers.
- FIGURE 18 is a graph of nanoparticle size for the homopolymers and copolymers prepared from the monomers illustrated in FIGURE 17: 100% 2°, 100% 3°, 100% 4°, 75% 2725% 3°, 75% 3725% 4°, 75% 4725% 2°, 50% 2750% 3°, 50% 3750% 4°, 50% 4750% 2°, 25% 2775% 3°, 25% 3775% 4°, 25% 4775% 2°. It was found that the all polymers condensed DNA into nanoparticles small enough to enter the cells via clathrin- mediated endocytosis with the exception of 75% 4725% 2° and 50% 4750% 2° copolymers.
- FIGURE 19 is a graph of nanoparticle surface charge for the homopolymers and copolymers prepared from the monomers illustrated in FIGURE 17: 100% 2°, 100% 3°, 100% 4°, 75% 2725% 3°, 75% 3725% 4°, 75% 4725% 2°, 50% 2750% 3°, 50% 3750% 4°, 50% 4750% 2°, 25% 2775% 3°, 25% 3775% 4°, 25% 4775% 2°.
- AU 274° and 374° were positively charged, while all 273° were negatively charged.
- FIGURE 20 is a graph comparing transfection efficiency (COS-7 cells) of poly(ethyleneimine) (PEI) to the homopolymers and copolymers prepared from the monomers illustrated in FIGURE 17: 100% 2°, 100% 3°, 100% 4°, 75% 2725% 3°, 75% 3725% 4°, 75% 4725% 2°, 50% 2750% 3°, 50% 3750% 4°, 50% 4750% 2°, 25% 2775% 3°, 25% 3775% 4°, 25% 4775% 2°.
- COS-7 cells were transfected with the nanoparticles prepared via condensation of DNA by the mixed-amine polymers..
- FIGURE 21 is a graph comparing cell viability of cells transfected with poly(ethyleneimine) (PEI) to the homopolymers and copolymers prepared from the monomers illustrated in FIGURE 17: 100% 2°, 100% 3°, 100% 4°, 75% 2725% 3°, 75%
- PEI poly(ethyleneimine)
- FIGURE 22 is a graph comparing transfection with hydrolyzable tertiary amine CBMA ester or non-hydrolyzable tertiary amine dimethyl aminoethyl methacrylate.
- the invention provides polymers, materials made form the polymers, and methods for making and using the polymers and polymer materials.
- cationic polymers are provided.
- the cationic polymers of the invention include hydrolyzable groups that can be hydrolyzed to provide zwitterionic polymers.
- Zwitterionic polymers are polymers having a balance of positive and negative charge. Zwitterionic polymers can be highly resistant to protein adsorption and bacterial adhesion. Due to their biomimetic nature, zwitterionic polymers, such as phosphobetaine, sulfobetaine, and carboxybetaine polymers, exhibit high biocompatibility.
- Controlled Hydrolysis The variation of the structural features of the cationic polymers allows for their controlled hydrolysis and the control of the biological, chemical, and mechanical properties.
- the rate of hydrolysis can be significantly affected by and controlled by the selection of the nature of the hydrolyzable group (e.g., for esters,
- the cationic polymers of the invention advantageously release functional groups on hydrolysis.
- hydrolysis ester releases an -OR group.
- the released group can be a therapeutic agent (e.g., an antimicrobial, antibacterial, an antifungal agent).
- the cationic polymers can release their counter ions (X " ), which can also be therapeutic agents (e.g., nucleic acids, amino acids, peptides, proteins, and salicylate).
- conjugated DNAs or proteins can be released via the hydrolysis of a cationic polymer carrier when the complex reaches its target.
- antimicrobial agents antimicrobial cationic polymers can be converted to zwitterionic polymers, leaving no toxic residues in the environment or no killed microbes on a surface.
- hydrolyzable group can be cleaved not only by hydrolysis, but also by cleavage (e.g., degradation or erosion) that occurs by other means.
- cleavage e.g., degradation or erosion
- the cationic polymers can be converted to their corresponding zwitterionic polymers by environmental changes due to enzymatic catalysis, redox, heat, light, ionic strength, pH, and hydrolysis, among others.
- cleavage likely occurs by enzymatic action and/or pH change.
- the cationic polymers of the invention include hydrolyzable groups that, when hydrolyzed, provide anionic groups that render the polymer zwitterionic.
- the number of hydrolyzable groups is substantially equal to the number of cationic groups such that, when the hydrolyzable groups are hydrolyzed, in the resulting polymer is zwitterionic.
- the term "zwitterionic polymer” refers to a polymer having substantially equal numbers of cationic groups and anionic groups.
- cationic polymers of the invention have formula (I):
- the average molecular weight of the polymers of formula (I) is from about 1 k
- the polymer of formula (I) includes n pendant groups and can be prepared by polymerization of monomers having formula (III):
- R d is selected from hydrogen, fluorine, trifluoromethyl, C1-C6 alkyl, and C6-C12 aryl groups.
- PB is the polymer backbone.
- Representative polymer backbones include vinyl backbones (i.e., -C(R')(R")-C(R'")(R"")-, where R', R", R'", and
- R'" are independently selected from hydrogen, alkyl, and aryl) derived from vinyl monomers (e.g., acrylate, methacrylate, acrylamide, methacrylamide, styrene).
- suitable backbones include polymer backbones that provide for pendant cationic groups that include hydrolyzable groups that can be converted to zwitterionic groups, and backbones that include cationic groups and that provide for pendant hydrolyzable groups that can be converted to zwitterionic groups.
- Other representative polymer backbones include peptide (polypeptide), urethane (polyurethane), and epoxy backbones.
- CH 2 C(Rd)- is the polymerizable group. It will be appreciated that other polymerizable groups, including those noted above, can be used to provide the monomers and polymers of the invention.
- N + is the cationic center.
- the cationic center is a quaternary ammonium (N bonded to L 1 ; R a , R b , and L 2 ).
- other useful cationic centers include imidazolium, triazaolium, pyridinium, morpholinium, oxazolidinium, pyrazinium, pyridazinium, pyrimidinium, piperazinium, and pyrrolidinium.
- R a and R b are independently selected from hydrogen, alkyl, and aryl groups.
- Representative alkyl groups include Cl-ClO straight chain and branched alkyl groups.
- the alkyl group is further substituted with one of more substituents including, for example, an aryl group (e.g., -CH 2 C O H S , benzyl).
- R a and R b are methyl.
- Representative aryl groups include C6-C12 aryl groups including, for example, phenyl.
- R 2 or R 3 is absent.
- L 1 is a linker that covalently couples the cationic center to the polymer backbone.
- L 1 includes a functional group (e.g., ester or amide) that couples the remainder of L 1 to the polymer backbone (or polymerizable moiety for the monomer of formula (III)).
- L 1 can include an C1-C20 alkylene chain.
- L 2 is a linker that covalently couples the cationic center to the hydrolyzable group
- L 2 can be a C1-C20 alkylene chain.
- Representative L 2 groups include -(CH 2 ) n -, where n is 1-20 (e.g., 1, 3, or
- the hydrophobicity and the rate of hydrolysis of the cationic polymers of formula (I) can be controlled by L 1 and/or L 2 .
- the greater the hydrophobicity of L 1 or L 2 the slower the hydrolysis of the hydrolyzable group and the conversion of the cationic polymer to the zwitterionic polymer.
- the hydrolyzable group can be an ester, such as a carboxylic acid ester (A is C), a sulfinic acid ester (A is S), a sulfonic acid ester (A is SO), a phosphinic acid ester (A is P), or a phosphonic acid ester (A is PO).
- the hydrolyzable group can also be an anhydride.
- R c is an alkyl, aryl, acyl, or silyl group that may be further substituted with one or more substituents.
- alkyl groups include C1-C30 straight chain and branched alkyl groups.
- the alkyl group is further substituted with one of more substituents including, for example, an aryl group (e.g., -CH 2 C O H S , benzyl).
- R c is a C1-C20 straight chain alkyl group.
- R c is methyl.
- R c is ethyl.
- R c is a C3-C20 alkyl.
- R c is a C4-C20 alkyl. In one embodiment, R c is a C5-C20 alkyl. In one embodiment, R c is a C6-C20 alkyl. In one embodiment, R c is a C8-C20 alkyl. In one embodiment, R c is a C10-C20 alkyl. For applications where relatively slow hydrolysis is desired, R c is a C4-C20 n-alkyl group or a C4-C30 n-alkyl group.
- Representative aryl groups include C6-C12 aryl groups including, for example, phenyl including substituted phenyl groups (e.g., benzoic acid).
- silyl groups include silyl groups where R is C1-C20 alkyl or C6-C12 aryl.
- the hydrolysis product R C O " is a therapeutic agent (e.g., an antimicrobial agent, such as salicylic acid (2-hydroxybenzoic acid), benzoate, lactate, and the anion form of antibiotic and antifungal drugs).
- the hydrolysis product R C O " (or R C OH) is a lactate, glycolate, or amino acid.
- the rate of hydrolysis of the cationic polymers of formula (I) can also be controlled by R c .
- the slower the hydrolysis of the hydrolyzable group due to, for example, steric and/or kinetic effects due to R c the slower the conversion of the cationic polymer to the zwitterionic polymer.
- X " is the counter ion associated with the cationic center.
- the counter ion can be the counter ion that results from the synthesis of the cationic polymer of formula (I) or the monomers of formula (III) (e.g., Cl “ , Br “ , I " ).
- the counter ion that is initially produced from the synthesis of the cationic center can also be exchanged with other suitable counter ions to provide polymers having controllable hydrolysis properties and other biological properties.
- the rate of hydrolysis of the cationic polymers of formula (I) can be controlled by the counter ion. The more hydrophobic the counter ion, the slower the hydrolysis of the hydrolyzable group and the slower the conversion of the cationic polymer to the zwitterionic polymer.
- counter ions also can be chosen from chloride, bromide, iodide, sulfate; nitrate; perchlorate (ClO 4 ); tetrafluoroborate (BF 4 ); hexafluorophosphate (PFe); trifluoromethylsulfonate (SO 3 CF 3 ); and derivatives thereof.
- suitable counter ions include hydrophobic counter ions and counter ions having therapeutic activity (e.g., an antimicrobial agent, such as salicylic acid (2-hydroxybenzoic acid), benzoate, lactate, and the anion form of antibiotic and antifungal drugs).
- R d is selected from hydrogen, fluoride, trifluoromethyl, and C1-C6 alkyl (e.g., methyl, ethyl, propyl, butyl).
- R d is hydrogen.
- R d is methyl.
- R d is ethyl.
- the variation of the structural features of the cationic polymers allows for their controlled hydrolysis and the control of the biological, chemical, and mechanical properties.
- the structural features of the cationic polymers noted above that can be varied to achieve the desired controlled hydrolysis of the polymer include L 1 , L 2 , R a , R b , A, R c , and X " .
- the more hydrophobic the polymer or the noted structural feature the slower the hydrolysis of the cationic polymer to the zwitterionic polymer.
- the cationic polymer of the invention include homopolymers, random copolymers, and block copolymers.
- the invention provides cationic homopolymers, such as defined by formula (I), prepared by polymerizing a cationic monomer, such as defined by formula (III). It will be appreciated that the advantageous properties associated with cationic polymers of the invention including those polymers defined by formula (I) can be imparted to other polymeric materials.
- the invention provides random copolymers prepared by copolymerizing two different cationic monomers of formula (III).
- the invention provides random copolymers that include cationic repeating units prepared by copolymerizing one or more cationic monomers of the invention defined by formula (III) with one or more other monomers
- hydrophobic monomers e.g., hydrophobic monomers, anionic monomers, or zwitterionic monomers, such as phosphorylbetaine, sulfobetaine, or carboxybetaine monomers.
- the invention provides block copolymers having one or more blocks comprising cationic repeating units and one or more other blocks.
- the one or more blocks that include cationic repeating units include only cationic repeating units (e.g., homo- or copolymer prepared from cationic monomers of formula (III)).
- the one or more blocks that include cationic repeating units include cationic repeating units and other repeating units (e.g., hydrophobic, anionic, zwitterionic repeating units).
- Other Suitable Polymers include e.g., hydrophobic, anionic, zwitterionic repeating units.
- the invention also provides the following polymers.
- the cationic polymer has the following structure:
- R any alkyl chain, aromatic or lactate or glycolate
- R' any alkyl chain or aromatic group.
- the cationic polymer has the following structure:
- R 1 H, or alkyl chain
- R 2 no atom, H, or alkyl chain
- R 3 alkyl chain.
- the invention provides a polymer having the following structure:
- R 1 is any alkyl chain
- R 3 is any alkyl chain
- the invention provides a polymer having the following structure:
- the invention provides a polymer having the following structure:
- the invention provides a polymer having the following structure:
- R' any alkyl chain, aromatic group.
- the invention provides polymers having the following structure:
- R any alkyl chain, aromatic or lactate or glycolate
- R' any alkyl chain, aromatic group.
- the invention provides a polymer having the following structure:
- the invention provides a polymer having the following structure:
- R H or alkyl chain.
- the invention provides a polymer having the following structure:
- R 1 any alkyl chain
- the invention provides a polymer having the following structure:
- R 1 any alkyl chain.
- FIGURE 1 Three representative cationic monomers of formula (III) useful for making cationic polymers of formula (I), and ultimately the zwitterionic polymers of formula (II) are illustrated in FIGURE 1.
- Polymerization of the monomers provides the corresponding cationic polymers.
- the three monomers were polymerized using free radical polymerization to form linear polymers, or using surface-initiated ATRP to prepare polymer brushes on SPR sensors.
- the polymers with different spacer groups (L 2 ) and ester groups were expected to have different chemical, physical and biological properties.
- the synthesis of the three monomers and their polymerizations are described in Example 1.
- Hydrolysis of the cationic polymers provides the zwitterionic polymers (i.e., zwitterionic polycarboxybetaines).
- the hydrolysis of representative cationic polymer of the invention is described in Example 2 and illustrated schematically in FIGURE 2.
- n is 1, 3, or 5 (corresponding to polyCBAA-1 -ester, polyCBAA-3-ester, and polyCBAA-5-ester, respectively).
- the three carboxybetaine ester polymers were dissolved under different sodium hydroxide concentrations and their hydrolysis behavior was studied. After a period of time, the hydrolysis rate of the polymers was analyzed by measuring the retaining ester groups on the polymer using 1 H NMR.
- FIGURE 3 illustrates the NMR spectra of polyCBAA-3- ester after a one-hour treatment with three different concentrations of NaOH.
- NaOH solution with a concentration of 10 mM, only slightly hydrolysis was detected (ca. 3%).
- 100 mM NaOH solution about 82% polymer was hydrolyzed.
- NaOH concentration of 1 M the polymer was totally hydrolyzed in one hour.
- FIGURE 4 graphs the hydrolysis rate under 100 mM or 10 mM NaOH as a function of time. Referring to FIGURE 4, under these two NaOH concentrations, most hydrolysis happens in the first hour. After that, the hydrolysis rate changes only slightly with the time.
- the hydrolysis rate of the cationic polymers of the invention can be controlled by modifying their structures.
- cationic polymers having varying structure parameters such as ester groups (hydrolyzable groups), spacer groups (L 1 and L 2 ), and counter ions (X " ).
- Hydrolysis behavior can also be controlled by varying polymer molecular weight or copolymerizing with other monomers.
- Hydrolyzable ester groups such as t-butyl and alkyl substituted silyl
- anhydride groups can be easily hydrolyzed under acidic or basic condition.
- Changing spacer groups (L 2 : -CH 2 ) n -) between the quaternary ammonium groups (cationic center) and the ester (hydrolyzable) groups also can tune the hydrolysis rate. Short spacers can increase the hydrolysis rate.
- counter ions such as hydrophilic anions (e.g., CI “ , Br “ , I “ , SO 4 ) also increase the hydrolysis rate, and low polymer molecular weight and copolymerization with other hydrophilic monomers also help to increase the hydrolysis rate.
- the hydrolyzable cationic polymers of the invention can advantageously be used as materials effective in reducing protein adsorption to surfaces treated with the polymers.
- the cationic polymers can be used to prepare low-fouling surfaces. These surfaces can be advantageously employed for devices in environments where the protein adsorption to device surfaces are detrimental.
- polymer brushes were prepared from representative cationic polymers as described in Example 3 and their protein adsorption measured.
- the three monomers (CBAA-I -ester, CBAA-3-ester, and CBAA-5-ester) were grafted on the surfaces of a SPR sensor using surface-initiated ATRP.
- the polymer brushes had a thickness of 5-20 nm estimated from XPS analysis. Protein adsorption from a 1 mg/mL fibrinogen solution on the three polymer brushes was measured using SPR. Fibrinogen is a sticky protein and plays an important role in platelet aggregation and blood clotting on biomaterials.
- Fibrinogen adsorption was 195 ng/cm 2 , 255 ng/cm 2 , and 600 ng/cm 2 for polyCBAA-1 -ester, polyCBAA-3-ester, and polyCBAA-5-ester, respectively (see FIGURES 5A-5C). All three polymers have evident protein adsorption due to their positive charges. PoIyCBAA- 1 -ester had relatively lower fibrinogen adsorption due to its higher hydrophilicity compared to the other two esters having more hydrophobic L 2 (i.e., C3 and C5, respectively). With the increase in L 2 from methylene to propylene to pentylene, the hydrophobicity of the polymer increases, leading to higher fibrinogen adsorption.
- FIGURES 5A-5C illustrate that the surfaces grafted with each of the three polymers were converted to surfaces that were highly resistant to fibrinogen adsorption.
- fibrinogen adsorption is less than 0.3 ng/cm 2 , which is the detection limit of the SPR.
- Fibrinogen adsorption on hydrolyzed polyCBAA-5-ester was about 1.5 ng/cm 2 .
- hydrolyzable cationic polymers of the invention exhibit antimicrobial properties.
- the evaluation of antimicrobial properties of representative cationic polymers of the invention is described in Example 4.
- polymer solutions of polyCBAA-1 -ester, polyCBAA-3-ester, and polyCBAA-5-ester were incubated with E. coli. It was found that at a concentration of 2 mM (repeat unit molar concentration), polyCBAA-1 -ester, polyCBAA-3-ester, and polyCBAA-5-ester present a live cell percentage of 95%, 87.3%, and 46.2%, respectively (see FIGURE 6). Antimicrobial activities appears to increase with the increase in the length of L 2 .
- the zwitterionic polymers After hydrolysis, the zwitterionic polymers, polyCBAA-1, polyCBAA-3, and polyCBAA-5, exhibit a live cell percentage of 93.7%, 96.3% and 95.3%, respectively, indicating that the antimicrobial activity decreases with the hydrolysis of the cationic polymers (i.e., polycarboxybetaine esters) to the zwitterionic polymers (i.e., polycarboxybetaines).
- the cationic polymers i.e., polycarboxybetaine esters
- the zwitterionic polymers i.e., polycarboxybetaines
- the antimicrobial efficacy of the polyCBAA-5-ester is comparable to that of other quaternized polymers with similar alkyl chain length. Higher antimicrobial efficacy can be achieved with longer alkyl chain lengths (e.g., C1-C20).
- antimicrobial coatings made from the cationic polymers of the invention are hydrolyzed to zwitterionic polymers to provide surfaces that are highly resistant to the adsorption of various biomolecules.
- These zwitterionic polymers are nontoxic, biocompatible, and nonfouling, both as bulk materials and surface coatings.
- polycarboxybetaines hydrogels were non-cytotoxic and contain less than 0.06 units (EU)/mL of endotoxin using a Limulus Amebocyte Lysate (LAL) endotoxin assay kit (Cambrex Bioscience. Walkerville, MD).
- LAL Limulus Amebocyte Lysate
- the polycarboxybetaine hydrogels were implanted subcutaneously within mice for up to four weeks. The results showed that the polycarboxybetaines have in vivo biocompatibility comparable to that of poly(2-hydroxyethyl methacrylate (polyHEMA) hydrogels, a well-accepted model biomaterial for implantation.
- poly(2-hydroxyethyl methacrylate (polyHEMA) hydrogels a well-accepted model biomaterial for implantation.
- the nontoxic properties of the zwitterionic polymers convert the toxicity of their cationic polymer precursors and further provide nonfouling properties that can prevent dead microbes and adsorbed proteins from accumulating on the surface. Switchable Polymer Coatings and Their Use in Medical Devices
- the cationic polymers of the invention can be advantageously used as coatings for the surfaces of a variety of devices including, for example, medical devices.
- the cationic polymers of the invention provide switchable biocompatible polymer surfaces having self- sterilizing and nonfouling capabilities.
- FIGURE 7 is a schematic illustration of a switchable biocompatible polymer surfaces having self- sterilizing and nonfouling capabilities.
- antimicrobial surface (a) is a surface coated with a representative cationic polymer of the invention (i.e., pCBMA-1 C2, see FIGURE 8) that effectively kills bacteria.
- pCBMA-1 C2 a representative cationic polymer of the invention
- the representative cationic polymer On hydrolysis (b) the representative cationic polymer is converted to a nonfouling zwitterionic polymer (i.e., pCBMA-1, the carboxylate corresponding to pCBMA-1 C2 ester) and dead bacteria remaining on the surface are released (c) from the nonfouling zwitterionic polymer (i.e., pCBMA-1) to provide a surface coated with the zwitterionic polymer, which is highly resistant to bacterial adhesion (d).
- the materials of the invention e.g., polymers, hydro gels
- the invention provides devices and materials having a surface (i.e., one or more surfaces) to which have been applied (e.g., coated, covalently coupled, ionically associated, hydrophobically associated) one or more materials of the invention.
- Representative devices that may be advantageously treated with a material of the invention, modified to include a material of the invention, or incorporates a material of the invention include: particle (e.g., nanoparticle) having a surface treated with, modified to include, or incorporates a material of the invention; drug carrier having a surface treated with, modified to include, or incorporates a material of the invention; non-viral gene delivery system having a surface treated with, modified to include, or incorporates a material of the invention; biosensor having a surface treated with, modified to include, or incorporates a material of the invention; devices for bioprocesses or bioseparations, such as membranes for microbial suspension, hormone separation, protein fractionation, cell separation, waste water treatment, oligosaccharide bioreactors, protein ultrafiltration, and diary processing having a surface treated with, modified to include, or incorporates a material of the invention; implantable sensor having a surface treated with, modified to include, or incorporates a material of the invention; subcutaneous sensor having a surface treated with,
- Microbial adhesion onto implanted biomaterials and the subsequent formation of biofilms is one of the major causes of biomedical device failure.
- the use of antimicrobial and nonfouling coatings are two strategies for the prevention of the attachment and spreading of microorganisms on the surfaces of implantable materials.
- Antimicrobial surfaces containing covalently linked quaternary ammonium compounds (QACs) have proved to be able to efficiently kill a variety of microorganisms.
- a major problem with QAC surfaces is the attachment of dead microorganisms remaining on antimicrobial coatings, which can trigger an immune response and inflammation, and block its antimicrobial functional groups.
- such antimicrobial coatings can not fulfill the requirements of nonfouling and biocompatibility as implantable biomaterials.
- PEG poly(ethylene glycol)
- zwitterionic polymers have been extensively used as nonfouling materials to reduce bacterial attachment and biofilm formation.
- PEG poly(sulfobetaine methacrylate)
- pSBMA poly(sulfobetaine methacrylate)
- zwitterionic coatings can reduce the initial attachment and delay colonization of microbes on surfaces, there is a possibility of introducing pathogenic microbes into the patient during implantation operations and catheter insertions, which results in the failure of implanted devices; the use of antimicrobial agents will then be necessary to eliminate these microbes.
- Surface-responsive materials have been developed for a broad spectrum of applications, but it is still a great challenge to develop biocompatible materials that have both antimicrobial and nonfouling capabilities.
- the present invention provides a switchable polymer surface coating that combines the advantages of both nonfouling surface and that can kill greater than 99.9% of Escherichia coli K12 in one hour, with 98% of the dead bacterial cells released when the cationic derivatives are hydrolyzed to nonfouling zwitterionic polymers.
- ATRP surface-initiated atom transfer radical polymerization
- the thicknesses of the obtained polymer coatings as measured by atomic force microscopy (AFM), were 26-32 nm (Table 1).
- the bactericidal activity of pCBMA-1 C2 surfaces was determined using E. coli Kl 2, according to a modified literature procedure (Tiller et al., Proc. Natl. Acad. ScL USA 98:5981, 2001).
- the antimicrobial efficiency was defined as the amount of live cells on the tested surfaces relative to those on the pCBMA-2 surface.
- FIGURE 9 shows that pCBMA-1 C2 and pC8NMA surfaces kill greater than 99.9% and 99.6 %, respectively, of the E. coli in one hour relative to pCBMA-2 surfaces.
- the total number of live bacterial cells on the gold surface, which was also used as a negative- control surface, is similar to that on the pCBMA-2 surface.
- FIGURES 10A- 1OF show that large amounts of bacteria were attached to the cationic pCBMA-1 C2 and pC8NMA surfaces before hydrolysis, whereas very few bacterial cells were attached to the zwitterionic pCBMA-2 surface.
- pCBMA-1 C2 released the majority of cells after hydrolysis while pCBMA-2 remained nonfouling.
- FIGURE 11 shows quantitative data for the amount of bacterial cells remaining on all three polymer surfaces before and after hydrolysis. There were similar amounts of bacterial residues on both cationic pCBMA-1 C2 and pC8NMA surfaces before hydrolysis, while the amount of attached cells on the pCBMA-2 surface is less than 0.3% of that on both cationic pCBMA-1 C2 and pC8NMA surfaces.
- the three surfaces were incubated in N-cyclohexyl-3- aminopropanesulfonic acid (CAPS) buffer (10 mM, pH 10.0) at 37 0 C for 8 days.
- CAPS N-cyclohexyl-3- aminopropanesulfonic acid
- the pCBMA-1 C2 surfaces were hydrolyzed to poly(N-(carboxymethyl)-N,N-dimethyl-2-[(2- methyl-l-oxo-2-propen-l-yl)-oxy]ethanaminium) (pCBMA-1) and 98% of the dead bacterial cells were released. In contrast, no release of the dead cells was observed on pC8NMA surfaces fp > 0.1) while pCBMA-2 surfaces retained very low bacterial adhesion. The release of the attached bacterial cells is dependent on the conversion of cationic pCBMA-1 C2 into zwitterionic pCBMA-1.
- Hydrolysis rate of betaine esters is influenced by several factors, such as the length of the spacer (L 2 ) between the quaternary amine and the carboxyl groups, the nature of the hydrolyzable group, temperature, 1 and pH value. The majority of polymer chains of the ester group used were hydrolyzed. The hydrolysis rate of the betaine esters is also slower after bacterial cells and proteins are attached to the surface.
- pCBMA-1 C2 which has one methylene spacer (L 2 ), was chosen and the experimental temperature was set at 37 0 C to achieve a fast hydrolysis rate and to provide a physiologically relevant temperature.
- Nonspecific protein adsorption on various surfaces was measured by a surface plasmon resonance (SPR) sensor to determine the nonfouling characteristics of the surfaces (see Table 2).
- Hydrolysis conditions for pCBMA-1 C2 and control surfaces were investigated in situ in the SPR sensor.
- FIGURES 12A and 12B show representative SPR sensorgrams for fibrinogen adsorption on pCBMA-1 C2 and control surfaces over time. The fibrinogen adsorption on pCBMA-1 C2 before hydrolysis was 229.2 ng cm "2 .
- the pCBMA-2 surface still exhibited excellent nonfouling properties, with less than 2 ng cm "2 fibrinogen absorption. This result indicates that the obtained zwitterionic surfaces are highly resistant to protein adsorption and are qualified as ultralow fouling surfaces, which are required for the surface coatings of implantable medical devices.
- the invention provides a switchable polymer surface that integrates antimicrobial and nonfouling properties and is biocompatible.
- the representative cationic polymer i.e., precursor of pCBMA
- pCBMA cationic polymer
- the switchable process from antimicrobial to nonfouling surfaces can be tuned through adjusting the hydrolysis rate of these polymers for specific requirements of applications.
- the cationic polymers of the invention can include a hydrophobic counter ion or a counter ion having therapeutic activity (e.g., antimicrobial or antibacterial activity.
- a representative polymer having a salicylate counter ion (polyCBMA- 1 C2) can be prepared from the monomer illustrated in FIGURE 13: CBMA-I C2 ("1" indicates one carbon between two charged groups and "C2" indicates C2 ester).
- SA salicylic acid
- the release of SA into the aqueous phase was measured by high performance liquid chromatography (HPLC).
- the release rate of SA is defined as the amount of released SA divided by time (mg/h).
- the release rate of SA from pCBMA- 1 C2 SA hydrogel depends on temperature, ionic strength, and pH.
- FIGURE 14 and FIGURE 15 indicated that higher pH promotes the release of SA and that increased ionic strength can slightly increase the release rate of SA. By comparing FIGURE 14 and FIGURE 15, it can be observed that the elevated temperature results in a faster release of SA in water and phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- the release rate of SA decreases as a function of time for all the conditions.
- therapeutic agent delivery systems are provided.
- the cationic polymers of the invention advantageous act as carriers in the delivery of therapeutic agents that can be reversibly associated with the polymers.
- the therapeutic agent delivery system includes a polymer of the invention and a therapeutic agent that is reversibly associative with the polymer.
- reversibly associative refers to a therapeutic agent that can be effectively condensed (i.e., packaged or bound) through an associative interaction (e.g., ionic) with the cationic polymer and then released once the delivery system reaches its target.
- Suitable therapeutic agents include small molecules, nucleic acids (e.g., genes), proteins, and peptides having charge properties sufficient to be associated to the cationic polymers during transport to the target where the therapeutic agent dissociates from the polymer as a result of hydrolysis of the cationic polymer and its conversion to the corresponding zwitterionic polymer at the target of interest.
- the therapeutic agent is a nucleic acid such as a DNA, RNA, or siRNA.
- the polymer is a copolymer.
- Representative copolymers have first repeating units and second repeating units. Suitable first repeating units include tertiary (3°) amine groups and suitable second repeating units include primary (1°), secondary (2°), or quaternary (4°) amine groups. These copolymers can be designated 371°, 372°, and 374°.
- the second repeating units include quaternary amine groups (e.g., 374° copolymer).
- the copolymers are random copolymers.
- the copolymers are block copolymers.
- the invention provides methods for administering a therapeutic agent using a cationic polymer of the invention.
- a therapeutic agent is administered to a subject in need thereof by administering the therapeutic agent delivery system.
- the method includes administering an effective amount of the therapeutic agent delivery system.
- the term "effective amount” refers to an amount of the delivery system that includes an amount of the therapeutic agent sufficient to affect the desired therapeutic action.
- Those skilled in the art can readily determine the effective amount of a therapeutic agent based on the subject, condition to be treated, and method of administration. The preparation and usefulness of representative cationic polymers of the invention in nucleic acid delivery is described in Example 5.
- FIGURE 16 shows the migration of the plasmid DNAs on an agarose gel, which can separate polymers or complexes based on their charge and size through agarose gel electrophoresis retardation.
- Band 1 includes DNA only. With the addition of the polymer solutions, only one band with high molecular weight was found for each case indicating that all three cationic polymers condense plasmid DNAs and form DNA/polymer complexes (bands 2, 4, and 6).
- PoIyCBAA- 1- ester/DNA complexes exhibited a strong dye signal.
- the agarose gel electrophoresis retardation shows the evident change before and after hydrolysis.
- the three polymer solutions were unable to complex plasmid DNA and all DNA in the mixtures were migrated on the agarose gel (see bands 3, 5, and 7).
- each of the three polymers, polyCBAA-1- ester, polyCBAA-3-ester, and polyCBAA-5-ester formed complexes with an average diameter of 106, 136, and 112 nm, respectively.
- the particles are well formed with low polydispersity (Table 2).
- polymer/DNA complexes To allow internalization by cells, smaller sizes of polymer/DNA complexes (less than 150 nm) are desired. Results show that all three polymers can condense DNA with appropriate sizes for gene deliver carriers. All three polymer/DNA complexes bear positive charges that allow for ready dispersion in solution.
- Table 2 Average effective diameters, polydispersities, and average ⁇ -potentials of DNA/polymer complexes formed from a plasmid DNA and three polycarboxybetaine esters.
- the cationic polymer of the invention interact with negatively charged DNAs.
- the results show that the cationic polymers of the invention not only form polymer/DNA complexes, but also release DNAs after hydrolysis.
- the products of hydrolysis zwitterionic polymers (e.g., polycarboxybetaines), are nontoxic, biocompatible, and nonfouling.
- the polymers with the carboxybetaine ester groups can be hydrolyzed through esterases.
- Polycarboxybetaine esters with different spacer groups (L 1 and/or L 2 ), alcohol components of esters groups such as benzyl ester can be prepared for the controllable hydrolysis intracellularly.
- tertiary amines can be introduced as "proton sponge.” Tertiary amines have pKa values around the physiological range. This property is advantageous for intracellular delivery because these amines can buffer endosomal compartments where the influx of protons causes acidification and potential DNA degradation. Amine-mediated binding of protons results in the formation of an osmotic gradient between the endosome and cytosol that can lead to vesicle swelling and rupture, known as the proton sponge effect.
- CBMA carboxybetaine methacrylate
- the 50/50 374° copolymer was an order- of -magnitude more efficient at transfection than the other copolymers. After transfection, the transfected cell colonies were tested for protein content as a measure of cell viability. It was found that all mixed-amine nanoparticles (with two exceptions) had as-good-as, if not better, cell viability than those cells treated only with medium. Transfection efficiency and cell viability of the mixed-amine nanoparticles were compared to poly(ethyleneimine) (PEI), which is widely considered as the standard for polymeric gene delivery. See FIGURE 20.
- PEI poly(ethyleneimine)
- the 50/50 mixture of 3° and 4° CBMA esters had equivalent transfection efficiency as PEI, within error (3.3x10 6 + 1x10 6 RLU/well for CBMA compared with 3.IxIO 6 + 4xlO 5 RLU/well for PEI).
- the cell viability of almost all polymers was an improvement over the cell viability of cells treated only with medium, and the 50/50 mixture of 3° and 4° CBMA esters specifically exhibited a 2-fold increase.
- PEI on the other hand, had only 12% cell viability in our system. See FIGURE 21.
- the 50/50 mixture of 3° and 4° CBMA ester copolymer has the same transfection ability as PEI and provides a 25-fold increase in cell viability.
- DMAEMA dimethyl aminoethyl methacrylate
- DMAEMA monomer was copolymerized with the same 2° and 4° monomers, the resulting copolymers exhibited only baseline transfection, indicating that the hydrolysis of the ethyl ester group is the key to the transfection ability of the 3° CBMA esters. See
- the success of the copolymer prepared from the 50/50 mixture of 3° and 4° CBMA esters can be attributed to its balance of positive charges, which allow it to package the DNA into discretely sized and positively charged nanoparticles, and tertiary amines, which allow endosomal buffering. These characteristics are further enhanced by the ability of the polymer side-chains to hydrolyze to release DNA and leave a non-fouling and biocompatible side-product.
- N-(3-dimethylaminopropyl) acrylamide (>98%) was purchased from
- Fibrinogen fraction I from bovine plasma
- PBS phosphate buffer saline
- Ethanol absolute 200 proof
- Water used in experiments was purified using a Millipore water purification system with a minimum resistivity of 18.0 M ⁇ .cm.
- ⁇ -Mercaptoundecyl bromoisobutyrate (1) was synthesized through reaction of
- CBAA- 1 -ester (2-carboxymethyl)3-acrylamidopropyldimethylammonium bromide, methyl ester.
- N-(3-dimethylaminopropyl)acrylamide 25 mmol
- methyl bromoacetate 37.5 mmol
- acetonitrile 25 mL
- CBAA-3-ester (4-carboxypropyl)3-acrylamidopropyldimethylammonium bromide, ethyl ester.
- N-(3-dimethylaminopropyl)acrylamide 50 mmol
- ethyl 4-bromobutyrate 60 mmol
- acetonitrile 25 mL
- the mixture was stirred under a nitrogen atmosphere for three days at room temperature.
- the solvent was removed on a rotary evaporator to get a colorless oil (92% yield).
- CBAA-5-ester (6-carboxypentyl)3-acrylamidopropyldimethylammonium bromide, ethyl ester. N-(3-dimethylaminopropyl)acrylamide (50 mmol), ethyl 6-bromohexanoate (55 mmol), and acetonitrile (25 mL) were added into a 100-mL round-bottom flask. The mixture was stirred under a nitrogen atmosphere for five days at 45 0 C. The solvent was removed on a rotary evaporator to get a slightly yellowish oil (87% yield).
- polyCBAA- 1-ester 1.62 (br, 2H), 2.05 (br, 3H), 3.25-3.32 (br, 8H), 3.62 (br, 2H), 3.83 (s, 3H), 4.38 (s, 2H); polyCBAA-3-ester 1.21 (t, 3H), 1.61 (br, 2H), 2.04 (br, 5H), 2.50 (t, 2H), 3.37 (br, 6H), 3.12 (s, 6H), 4.14 (q, 2H); polyCBAA-5-ester: 1.22 (t, 3H), 1.37 (m, 2H), 1.62-1.80 (br m, 6H), 2.01 (br, 3H), 2.39 (t, 2H), 3.03 (s, 6H), 3.24 (br m, 6H), 4.12 (q, 2H).
- the molecular weight of linear polyCBAA was estimated using a Waters Alliance 2695 Separations Module equipped with a Waters Ultrahydrogel 1000 column and detected with a Waters 2414 Reflex Detector.
- the mobile phase was an aqueous solution at a flow rate of 0.5 mL/min.
- the instrument and column were calibrated with poly(ethylene oxide) standards from Polymer Laboratories. All measurements were performed at 35 0 C.
- the molecular weight of the polymer was calculated using Empower Pro from Waters.
- NaOH solutions with different concentration (10 mM, 100 mM, and 1 M) in a concentration of 50 mg/mL. After an appropriate time interval, the polymer solutions were neutralized with dilute HCl solution and the water was removed by vacuum.
- IH NMR spectroscopy (D 2 O) was performed to measure the degradation rate by determining the amount of intact ester groups and comparing with other non-hydrolyzable pendant groups as inner standards. The results are illustrated in FIGURE 3.
- Example 2 Representative Cationic Polymer Protein Adsorption and Release
- SPR surface plasmon resonance
- Protein adsorption was measured with a custom-built SPR sensor, which is based on wavelength interrogation.
- a SPR chip was attached to the base of the prism, and optical contact was established using refractive index matching fluid (Cargille).
- a dual- channel flow cell with two independent parallel flow channels was used to contain liquid sample during experiments.
- a peristaltic pump (Ismatec) was utilized to deliver liquid sample to the two channels of the flow cell.
- Fibrinogen solution of 1.0 mg/mL in PBS (0.15M, pH 7.4 ) was flowed over the surfaces at a flow rate of 0.05 mL/min.
- a surface- sensitive SPR detector was used to monitor protein- surface interactions in real time. Wavelength shift was used to measure the change in surface concentration (mass per unit area). The results are illustrated in FIGURES 5A-5C.
- E. coli Kl 2 were first cultured in separate pure cultures overnight at 37°C on LB agar plates, which was then incubated with shaking at 37 0 C for 24 h. Cultures on agar plates can be used for two weeks, if kept at 4°C. Several colonies were used to inoculate 25ml of LB (20 g/L). These initial cultures were incubated at 37°C with shaking at 100 rpm for 18 hours and were then used to inoculate a second culture of each species in 200 ml of appropriate medium. When the second suspended culture reached an optical density of 1.0 at 600nm, bacteria were collected by centrifugation at 8,000 x g for 10 min at 4°C. Cell pellets were washed three times with sterile phosphate buffered saline (PBS, pH7.4) and subsequently suspended in PBS to a final concentration of 10 8 cells/mL.
- PBS sterile phosphate buffered saline
- Exposure of bacterial cells to representative polymer solutions was started when the culture containing bacterial cells was added to above polymer suspension which was pre-equilibrated and shaken at 3O 0 C, and the mixture were incubated at room temperature for 30 min.
- the final solution contains ca. 10 8 cells/mL E. coli and 2 mM repeat unit concentration, which is the molar concentration of the repeat unit of the polymers (ca. 0.6-0.76 mg/mL based on molecular weight of CBAAs and CBAA-esters).
- Example 2 Representative Cationic Polymer Nucleic Acid Condensation and Release
- the cationic polymers prepared as described in Example 1 were evaluated for their nucleic acid condensation and release. Preparation of Polymer/DNA Complexes and Agarose Gel Retardation Assays.
- the three carboxybetaine ester polymers prepared as described in Example 1 were dissolved in water with a concentration of 50 mg/mL. The polymer solutions were then diluted to a concentration of 14-19 mg/mL using DMSO. Then, water was added to make a final concentration of polymer of 1.6-2.2 mg/mL. 500 ⁇ L polymer/DMSO/water solution was added very slowly to 1.5 ml DNA solution (34.5 ⁇ g/mL) to form complexes or nanoparticles under stirring.
- Dynamic laser light scattering and C potential measurements were made using a ZetaPALS dynamic light scattering detector (Brookhaven Instruments Corp., Holtsville, NY, USA; 15-mW laser, incident beam at 676 nm). Polymer/DNA complexes were prepared as described above and complexes were then diluted in 1.4 ml of 25 mM Hepes buffer, pH 7.2. Correlation functions were collected at a scattering angle of 90°, and particle sizes were calculated using the Dynamic Light Scattering Software (version 3.55). Average electrophoretic mobilities were measured using BIC PALS ⁇ potential analysis software (Ver 3.82). While illustrative embodiments have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98907307P | 2007-11-19 | 2007-11-19 | |
PCT/US2008/084095 WO2009067562A1 (en) | 2007-11-19 | 2008-11-19 | Cationic beataine precursors to zwitterionic betaines having controlled biological properties |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2227496A1 true EP2227496A1 (de) | 2010-09-15 |
EP2227496B1 EP2227496B1 (de) | 2014-10-29 |
Family
ID=40254461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08851463.3A Active EP2227496B1 (de) | 2007-11-19 | 2008-11-19 | Kationische betainvorläufer für zwitterionische betaine mit kontrollierten biologischen eigenschaften |
Country Status (8)
Country | Link |
---|---|
US (3) | US8268301B2 (de) |
EP (1) | EP2227496B1 (de) |
JP (2) | JP5474808B2 (de) |
CN (1) | CN101918462B (de) |
AU (1) | AU2008326438B2 (de) |
CA (1) | CA2705485C (de) |
MX (1) | MX2010005295A (de) |
WO (2) | WO2009067566A1 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110097277A1 (en) | 2005-08-25 | 2011-04-28 | University Of Washington | Particles coated with zwitterionic polymers |
US8366652B2 (en) | 2007-08-17 | 2013-02-05 | The Invention Science Fund I, Llc | Systems, devices, and methods including infection-fighting and monitoring shunts |
US20090048648A1 (en) * | 2007-08-17 | 2009-02-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Self-sterilizing device |
US8734718B2 (en) | 2007-08-17 | 2014-05-27 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component |
US9005263B2 (en) | 2007-08-17 | 2015-04-14 | The Invention Science Fund I, Llc | System, devices, and methods including actively-controllable sterilizing excitation delivery implants |
US8702640B2 (en) | 2007-08-17 | 2014-04-22 | The Invention Science Fund I, Llc | System, devices, and methods including catheters configured to monitor and inhibit biofilm formation |
US8706211B2 (en) * | 2007-08-17 | 2014-04-22 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having self-cleaning surfaces |
US8647292B2 (en) | 2007-08-17 | 2014-02-11 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states |
US8753304B2 (en) | 2007-08-17 | 2014-06-17 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter |
EP2227496B1 (de) * | 2007-11-19 | 2014-10-29 | University of Washington | Kationische betainvorläufer für zwitterionische betaine mit kontrollierten biologischen eigenschaften |
US9533006B2 (en) | 2007-11-19 | 2017-01-03 | University Of Washington | Marine coatings |
US20110160681A1 (en) * | 2008-12-04 | 2011-06-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems, devices, and methods including catheters having light removable coatings based on a sensed condition |
US20120041286A1 (en) | 2008-12-04 | 2012-02-16 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems, devices, and methods including implantable devices with anti-microbial properties |
US8585627B2 (en) | 2008-12-04 | 2013-11-19 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure |
KR20130000369A (ko) | 2009-09-25 | 2013-01-02 | 오리진 테크놀로지스 인코포레이티드 | 단백질 어레이 및 이의 용도 |
CN102770407A (zh) | 2009-11-06 | 2012-11-07 | 华盛顿大学商业中心 | 交联的两性离子水凝胶 |
EP2496267A4 (de) * | 2009-11-06 | 2016-02-17 | Univ Washington Ct Commerciali | Zwitterionische polymer-biokonjugate und entsprechende verfahren |
JP2013534909A (ja) * | 2010-05-21 | 2013-09-09 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッド | 両性イオン性試薬 |
US8857629B2 (en) | 2010-07-15 | 2014-10-14 | International Business Machines Corporation | Composite membrane with multi-layered active layer |
US8727135B2 (en) | 2010-09-01 | 2014-05-20 | International Business Machines Corporation | Composite filtration membranes and methods of preparation thereof |
US8709536B2 (en) | 2010-09-01 | 2014-04-29 | International Business Machines Corporation | Composite filtration membranes and methods of preparation thereof |
US8933173B2 (en) * | 2010-11-23 | 2015-01-13 | Chung Yuan Christian University | Surface anti-biomolecule agent |
US9022227B2 (en) | 2011-03-21 | 2015-05-05 | International Business Machines Corporation | Composite membranes and methods of preparation thereof |
US9541480B2 (en) | 2011-06-29 | 2017-01-10 | Academia Sinica | Capture, purification, and release of biological substances using a surface coating |
WO2013013220A2 (en) | 2011-07-20 | 2013-01-24 | University Of Washington Through Its Center For Commercialization | Photonic blood typing |
FR2979821B1 (fr) * | 2011-09-13 | 2013-10-25 | Oreal | Procede de traitement cosmetique employant un polymere ethylenique |
US10031138B2 (en) | 2012-01-20 | 2018-07-24 | University Of Washington Through Its Center For Commercialization | Hierarchical films having ultra low fouling and high recognition element loading properties |
US9561474B2 (en) | 2012-06-07 | 2017-02-07 | International Business Machines Corporation | Composite membrane with multi-layered active layer |
US9788765B2 (en) * | 2012-09-28 | 2017-10-17 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
EP2925378B1 (de) * | 2012-11-30 | 2019-10-16 | University of Massachusetts Medical School | Multifunktionale oberflächenbeschichtung von implantaten |
WO2014164487A1 (en) | 2013-03-11 | 2014-10-09 | Teleflex Medical Incorporated | Devices with anti-thrombogenic and anti-microbial treatment |
EP2992056A4 (de) * | 2013-05-03 | 2017-12-27 | Hempel A/S | Neuartige polysiloxanbasierte fäulnisfreisetzungsbeschichtungen |
WO2014210546A1 (en) | 2013-06-27 | 2014-12-31 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
WO2015073539A1 (en) * | 2013-11-12 | 2015-05-21 | St. Teresa Medical, Inc. | Hemostatic products |
US10495644B2 (en) | 2014-04-01 | 2019-12-03 | Academia Sinica | Methods and systems for cancer diagnosis and prognosis |
JP2016017130A (ja) * | 2014-07-08 | 2016-02-01 | 互応化学工業株式会社 | 細菌付着抑制性樹脂 |
US10112198B2 (en) | 2014-08-26 | 2018-10-30 | Academia Sinica | Collector architecture layout design |
US10272180B2 (en) * | 2014-09-09 | 2019-04-30 | University Of Washington | Functionalized zwitterionic and mixed charge polymers, related hydrogels, and methods for their use |
EP3202432B1 (de) * | 2014-10-02 | 2020-12-09 | Asahi Kasei Medical Co., Ltd. | Filter zur verarbeitung biologischer flüssigkeiten und filtervorrichtung |
WO2016138528A1 (en) * | 2015-02-27 | 2016-09-01 | Wayne State University | Methods and compositions relating to biocompatible implants |
EP3303420B1 (de) * | 2015-06-02 | 2022-04-06 | University of Washington | Freistehende anti-fouling-polymere, deren zusammensetzungen und zugehörige monomere |
US10828387B2 (en) | 2015-11-12 | 2020-11-10 | St. Teresa Medical, Inc. | Method of sealing a durotomy |
WO2017125368A1 (en) * | 2016-01-20 | 2017-07-27 | Akzo Nobel Coatings International B.V. | Coating composition for substrates immersed in water |
US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
EP3469008A1 (de) | 2016-06-13 | 2019-04-17 | Massachusetts Institute Of Technology | Biokompatible zwitterionische polymerbeschichtungen und hydrogele zur reduzierung von fremdkörperreaktion und fibrose |
WO2018226854A2 (en) | 2017-06-06 | 2018-12-13 | Wayne State University | Antifouling polymer coatings and reverse coating method |
CN107537059B (zh) * | 2017-10-01 | 2020-06-05 | 山东煜和堂药业有限公司 | 一种双组份可溶性两性离子水凝胶敷料及其制备方法 |
WO2019089717A1 (en) | 2017-11-02 | 2019-05-09 | St. Teresa Medical, Inc. | Fibrin sealant products |
US11993670B2 (en) | 2018-06-06 | 2024-05-28 | The Board Of Trustees Of The University Of Illinois | Zwitterionic biocompatible polymers, methods, and uses thereof |
CA3118953A1 (en) * | 2018-11-08 | 2020-05-14 | The Governing Council Of The University Of Toronto | Composition and device for preventing hypoglycemia and use thereof |
US11078394B2 (en) | 2019-03-04 | 2021-08-03 | Saudi Arabian Oil Company | Cationic coatings for improved nanoparticle transport in a carbonate reservoir |
CN112245590B (zh) * | 2020-10-14 | 2022-04-01 | 燕山大学 | 一种基于巯基化甜菜碱修饰的阿霉素衍生物、纳米药物及其制备方法 |
CN113336901B (zh) * | 2021-06-25 | 2022-10-11 | 河北圣泰材料股份有限公司 | 一种甜菜碱型两性离子聚合物的制备方法 |
IL309464A (en) * | 2021-06-28 | 2024-02-01 | Tufts College | Plant-inspired zwitterionic monomers, polymers and their uses |
JPWO2023074837A1 (de) * | 2021-10-29 | 2023-05-04 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3671502A (en) | 1970-11-12 | 1972-06-20 | Kendall & Co | Betaine copolymers with hydroxyalkylacrylates and hydroxyalkylmethacrylates |
US4138446A (en) | 1974-12-19 | 1979-02-06 | Sumitomo Chemical Company, Limited | Water-soluble high polymers and their preparation |
GB1510689A (en) | 1974-12-19 | 1978-05-10 | Sumitomo Chemical Co | Preparation of water-soluble cationic high polymer |
GB1528616A (en) * | 1975-06-04 | 1978-10-18 | Ciba Geigy Ag | Alkali-release mordants |
US4415388A (en) | 1981-06-22 | 1983-11-15 | Johnson & Johnson | Method of making absorbent bearing products |
JPS59199696A (ja) * | 1983-04-28 | 1984-11-12 | Oki Electric Ind Co Ltd | リン脂質類似構造を有する化合物及びポリマ−並びにその製造方法 |
US4493926A (en) | 1984-01-04 | 1985-01-15 | General Electric Company | Dissociating ionically cross-linked siloxane polymers |
US5204060A (en) | 1986-01-07 | 1993-04-20 | Berol Kemi Ab | Method for disinfection |
JPS63234007A (ja) | 1987-03-23 | 1988-09-29 | Kohjin Co Ltd | 水溶性が良好なカチオン性重合体 |
US4985023A (en) | 1988-05-09 | 1991-01-15 | Dow Corning Corporation | Antimicrobial superabsorbent articles |
US4931328A (en) | 1988-08-19 | 1990-06-05 | Hewlett-Packard Company | Capillary tube with reduced protein interactions and controllable electroosmotic flow |
DE69124903T2 (de) | 1990-10-01 | 1997-06-19 | Phillips Petroleum Co | Absorbierendes Polymer |
SU1780673A1 (ru) | 1991-04-19 | 1992-12-15 | Tashk Farmatsevticheskij I | Фуhгицидhoe cpeдctbo |
KR100225234B1 (ko) * | 1992-09-24 | 1999-10-15 | 손욱 | 콜레스테릭계 액정 화합물 및 이를 이용한 고분자 분산 액정표시소자 |
US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
US5714360A (en) | 1995-11-03 | 1998-02-03 | Bsi Corporation | Photoactivatable water soluble cross-linking agents containing an onium group |
EP0856539A1 (de) * | 1997-01-30 | 1998-08-05 | Mitsui Chemicals, Inc. | Vernetzte Polymere |
US7056532B1 (en) | 1997-06-13 | 2006-06-06 | Univ. Nebraska Bd. of Regents | Compositions for delivery of biological agents and methods for the preparation thereof |
US7547445B2 (en) | 1998-03-19 | 2009-06-16 | Surmodics, Inc. | Crosslinkable macromers |
US6361768B1 (en) | 1998-12-29 | 2002-03-26 | Pmd Holdings Corp. | Hydrophilic ampholytic polymer |
ES2317838T3 (es) | 1999-05-26 | 2009-05-01 | Rhodia Inc. | Polimeros en bloque, composiciones y metodos de utilizacion de espumas, detergentes para la lavanderia, agentes de aclarado para ducha y coagulantes. |
DK1189553T3 (da) | 1999-06-24 | 2004-07-26 | Abbott Vascular Devices Ltd | Ballon-ekspanderbar stent |
US6313246B1 (en) * | 1999-07-07 | 2001-11-06 | Nalco Chemical Company | High molecular weight zwitterionic polymers |
JP3853549B2 (ja) * | 1999-11-10 | 2006-12-06 | 花王株式会社 | 機能性アルコール放出物質 |
US6852816B2 (en) | 2000-10-06 | 2005-02-08 | Biocompatibles Uk Limited | Zwitterionic polymers |
DE10132173A1 (de) * | 2001-07-03 | 2003-01-23 | Goldschmidt Ag Th | Neue Betainester |
US20050058689A1 (en) | 2003-07-03 | 2005-03-17 | Reactive Surfaces, Ltd. | Antifungal paints and coatings |
DE10261750A1 (de) | 2002-12-30 | 2004-07-15 | Basf Ag | Ampholytisches Copolymer und dessen Verwendung |
SE0400073D0 (sv) | 2003-04-04 | 2004-01-14 | Appear Sweden Hb | Antibacterial material |
ATE497699T1 (de) | 2003-05-15 | 2011-02-15 | Arch Uk Biocides Ltd | Antimikrobielle zusammensetzung enthaltend eine polymerische biguanide und ein copolymer und deren verwendung |
US7291427B2 (en) | 2004-03-19 | 2007-11-06 | Fujifilm Corporation | Surface graft material, conductive pattern material, and production method thereof |
US20060183863A1 (en) | 2005-02-14 | 2006-08-17 | Ciphergen Biosystems, Inc. | Zwitterionic polymers |
TWI326691B (en) | 2005-07-22 | 2010-07-01 | Kraton Polymers Res Bv | Sulfonated block copolymers, method for making same, and various uses for such block copolymers |
KR20080047589A (ko) | 2005-09-06 | 2008-05-29 | 노버스 인터내쇼날 인코포레이티드 | 선박 오손 방지 코팅 조성물 |
US8124128B2 (en) | 2005-11-08 | 2012-02-28 | Industrial Technology Research Institute | Amphiphilic block copolymers and nano particles comprising the same |
FR2894585B1 (fr) | 2005-12-14 | 2012-04-27 | Rhodia Recherches Et Tech | Copolymere comprenant des unites zwitterioniques et d'autres unites, composition comprenant le copolymere, et utilisation |
DE102006004111B4 (de) | 2006-01-28 | 2015-11-19 | Wöhlk-Contact-Linsen GmbH | Kontaktlinsenmaterial |
FR2898067B1 (fr) | 2006-03-03 | 2008-05-30 | Rhodia Recherches & Tech | Modification de surfaces solides par des associations de polymeres |
US20080311045A1 (en) | 2007-06-06 | 2008-12-18 | Biovaluation & Analysis, Inc. | Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo |
EP2227496B1 (de) * | 2007-11-19 | 2014-10-29 | University of Washington | Kationische betainvorläufer für zwitterionische betaine mit kontrollierten biologischen eigenschaften |
-
2008
- 2008-11-19 EP EP08851463.3A patent/EP2227496B1/de active Active
- 2008-11-19 WO PCT/US2008/084099 patent/WO2009067566A1/en active Application Filing
- 2008-11-19 CN CN2008801224996A patent/CN101918462B/zh active Active
- 2008-11-19 AU AU2008326438A patent/AU2008326438B2/en not_active Ceased
- 2008-11-19 CA CA2705485A patent/CA2705485C/en not_active Expired - Fee Related
- 2008-11-19 US US12/274,218 patent/US8268301B2/en active Active
- 2008-11-19 WO PCT/US2008/084095 patent/WO2009067562A1/en active Application Filing
- 2008-11-19 MX MX2010005295A patent/MX2010005295A/es active IP Right Grant
- 2008-11-19 JP JP2010534289A patent/JP5474808B2/ja active Active
-
2010
- 2010-05-14 US US12/780,194 patent/US20100247614A1/en not_active Abandoned
-
2012
- 2012-09-14 US US13/619,589 patent/US8404224B2/en active Active
-
2013
- 2013-10-22 JP JP2013219057A patent/JP2014012861A/ja not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2009067562A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009067562A1 (en) | 2009-05-28 |
US20100247614A1 (en) | 2010-09-30 |
JP2014012861A (ja) | 2014-01-23 |
CN101918462A (zh) | 2010-12-15 |
US8268301B2 (en) | 2012-09-18 |
CA2705485A1 (en) | 2009-05-28 |
US20130011363A1 (en) | 2013-01-10 |
JP2011504526A (ja) | 2011-02-10 |
JP5474808B2 (ja) | 2014-04-16 |
US20090156460A1 (en) | 2009-06-18 |
CN101918462B (zh) | 2013-07-17 |
US8404224B2 (en) | 2013-03-26 |
EP2227496B1 (de) | 2014-10-29 |
CA2705485C (en) | 2016-03-08 |
MX2010005295A (es) | 2010-06-23 |
WO2009067566A1 (en) | 2009-05-28 |
AU2008326438A1 (en) | 2009-05-28 |
AU2008326438B2 (en) | 2014-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2227496B1 (de) | Kationische betainvorläufer für zwitterionische betaine mit kontrollierten biologischen eigenschaften | |
US8658192B2 (en) | Integrated antimicrobial and low fouling materials | |
Zhang et al. | The hydrolysis of cationic polycarboxybetaine esters to zwitterionic polycarboxybetaines with controlled properties | |
US8349966B2 (en) | Marine coatings | |
US10544312B2 (en) | Marine coatings | |
EP3191016B1 (de) | Funktionalisierte zwitterionische polymere und polymere mit gemischter ladung, zugehörige hydrogele und verfahren zu deren verwendung | |
Save et al. | Synthesis by RAFT of amphiphilic block and comblike cationic copolymers and their use in emulsion polymerization for the electrosteric stabilization of latexes | |
Roy et al. | Antibacterial cellulose fiber via RAFT surface graft polymerization | |
Shin et al. | Mussel-inspired copolyether loop with superior antifouling behavior | |
Zhao et al. | Probing structure–antifouling activity relationships of polyacrylamides and polyacrylates | |
Santos et al. | Increasing the antimicrobial activity of amphiphilic cationic copolymers by the facile synthesis of high molecular weight stars by supplemental activator and reducing agent atom transfer radical polymerization | |
TW201512333A (zh) | 具有活體物質的附著抑制能之離子複合材料及其製造方法 | |
Schönemann et al. | Sulfobetaine methacrylate polymers of unconventional polyzwitterion architecture and their antifouling properties | |
Sun et al. | Study on the Core–Shell Reversion of PSBMA-b-PLMA Nanoparticles for the Fabrication of Antifouling Coatings | |
US20120269870A1 (en) | Switchable polymers and surfaces with reversibly switchable properties | |
Lim et al. | Effects of halide anions on the solution behavior of double hydrophilic carboxy-sulfobetaine block copolymers | |
Lou et al. | Biocidal potency of polymers with bulky cations | |
EP4182361A1 (de) | Phosphonathaltige polymere zur unterdrückung der virulenz | |
JP5071613B2 (ja) | 水難溶性有効成分の付着化組成物及び水難溶性有効成分の付着方法 | |
EP3973934A1 (de) | Polykationisches polymer, zusammensetzung mit dem polykationischen polymer und produkt mit einer aktiven oberfläche mit dem polykationischen polymer | |
Cheng | Design and development of integrated ultralow fouling and antimicrobial zwitterionic materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100618 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17Q | First examination report despatched |
Effective date: 20101019 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C08F 20/38 20060101ALI20140514BHEP Ipc: A61Q 19/00 20060101ALI20140514BHEP Ipc: A61K 31/785 20060101ALI20140514BHEP Ipc: C08F 20/36 20060101AFI20140514BHEP |
|
INTG | Intention to grant announced |
Effective date: 20140526 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 693565 Country of ref document: AT Kind code of ref document: T Effective date: 20141115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008035141 Country of ref document: DE Effective date: 20141211 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 693565 Country of ref document: AT Kind code of ref document: T Effective date: 20141029 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20141029 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150129 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150228 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150302 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150130 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141130 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008035141 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141130 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141130 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20150730 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141119 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141119 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20081119 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602008035141 Country of ref document: DE Representative=s name: ZACCO LEGAL RECHTSANWALTSGESELLSCHAFT MBH, DE |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230519 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231012 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231024 Year of fee payment: 16 Ref country code: DE Payment date: 20231017 Year of fee payment: 16 |